Industry Reports

GlaxoSmithKline plc announced the start of a phase III development programme investigating daprodustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), as a treatment for anaemia associated with chronic kidney disease (CKD). The phase III programme...

Eli Lilly and Company announced that solanezumab did not meet the primary endpoint in the EXPEDITION3 clinical trial, a phase 3 study of solanezumab in people with mild dementia due to Alzheimer's disease (AD). Patients treated...

Sun Pharma announced the execution of definitive agreements by its wholly owned subsidiary, for the acquisition of 85.1% of JSC Biosintez, a Russian pharmaceutical company engaged in manufacture and marketing of pharmaceutical products in Russia and CIS region. ...

Novartis announced it has acquired Selexys Pharmaceuticals Corporation, a company specializing in development of therapeutics in certain hematologic and inflammatory disorders. Novartis exercised its right to acquire Selexys following receipt of results of the SUSTAIN study,...

Cumberland Pharmaceuticals , a U.S. specialty pharmaceutical company has entered into an Agreement to acquire the exclusive U.S. rights to Nordic Group B.V.'s innovative injectable methotrexate product line. The products are designed for the treatment of...

Sorrento Therapeutics, Inc. Virttu, based in Glasgow, Scotland, is a privately-held biopharmaceutical company focused on the development of oncolytic virus therapy for treatment of cancer. Virttu's lead product candidate Seprehvir® (HSV1716) is a Herpes Simplex Virus...

CSL Limited -At the American Heart Association (AHA) Scientific Sessions in New Orleans, Louisiana, held on 15 November 2016, CSL Behring announced positive results from AEGIS-I, a Phase 2b safety and proof of mechanism clinical study of CSL112, a...